NCT02619630View on ClinicalTrials.gov

Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)

PHASE2RecruitingINTERVENTIONAL
Enrollment

275

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2025

Conditions
T-cell Adult Acute Lymphoblastic Leukemia
Interventions
DRUG

nelarabine

"Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil \>1 Giga/Liter~for a maximum of 5 blocks"

Trial Locations (1)

75010

RECRUITING

Hematology, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER